Matches in SemOpenAlex for { <https://semopenalex.org/work/W2033021519> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2033021519 endingPage "474" @default.
- W2033021519 startingPage "472" @default.
- W2033021519 abstract "Women suffering from recurrent platinum-resistant ovarian carcinoma go through several lines of chemotherapy, but eventually fail all conventional chemotherapy options. After failing multiple other regimens, we offer patients fluorouracil (5-FU) in a weekly regimen with leucovorin. For those women who failed to react to multiple lines of treatment, 5-FU has been shown to be a reasonable option with reported response rates of 10% to 33%. We report our experience with 5-FU+leucovorin in this patient population.This is a retrospective chart review of women treated for recurrent ovarian carcinoma between January 2003 and December 2009. Women with recurrent ovarian carcinoma who had been treated with at least 3 previous chemotherapy regimens and had received 5-FU were eligible for the study. 5-FU and leuocovorin are given at 600 mg/m weekly for 6 weeks of an 8-week cycle. Patient charts were reviewed for demographics and disease history relevant to the administration of 5-FU. Response was assessed clinically and by CA125 levels.Fifty-three patients matching inclusion criteria received 5-FU during the study period. Twenty-five percent of patients achieved a partial response and 17% stable disease for an overall response rate of 42%. A median of 4 weekly doses was administered (range, 1 to 26). The median survival of the whole cohort was 10 weeks after the last dose of 5-FU was administered.In this population of heavily pretreated patients, a significant response to 5-FU can be achieved. Unfortunately, the response is short lived and mostly partial." @default.
- W2033021519 created "2016-06-24" @default.
- W2033021519 creator A5037201937 @default.
- W2033021519 creator A5070897214 @default.
- W2033021519 creator A5072585760 @default.
- W2033021519 creator A5078927220 @default.
- W2033021519 creator A5080431474 @default.
- W2033021519 creator A5089430831 @default.
- W2033021519 date "2013-10-01" @default.
- W2033021519 modified "2023-09-24" @default.
- W2033021519 title "The Use of Fluorouracil (5-FU) and Leucovorin in Women With Heavily Pretreated Advanced Ovarian Carcinoma" @default.
- W2033021519 cites W191780465 @default.
- W2033021519 cites W2185382554 @default.
- W2033021519 doi "https://doi.org/10.1097/coc.0b013e3182549399" @default.
- W2033021519 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22706176" @default.
- W2033021519 hasPublicationYear "2013" @default.
- W2033021519 type Work @default.
- W2033021519 sameAs 2033021519 @default.
- W2033021519 citedByCount "6" @default.
- W2033021519 countsByYear W20330215192015 @default.
- W2033021519 countsByYear W20330215192016 @default.
- W2033021519 countsByYear W20330215192020 @default.
- W2033021519 countsByYear W20330215192021 @default.
- W2033021519 crossrefType "journal-article" @default.
- W2033021519 hasAuthorship W2033021519A5037201937 @default.
- W2033021519 hasAuthorship W2033021519A5070897214 @default.
- W2033021519 hasAuthorship W2033021519A5072585760 @default.
- W2033021519 hasAuthorship W2033021519A5078927220 @default.
- W2033021519 hasAuthorship W2033021519A5080431474 @default.
- W2033021519 hasAuthorship W2033021519A5089430831 @default.
- W2033021519 hasConcept C121608353 @default.
- W2033021519 hasConcept C126322002 @default.
- W2033021519 hasConcept C141071460 @default.
- W2033021519 hasConcept C143998085 @default.
- W2033021519 hasConcept C167135981 @default.
- W2033021519 hasConcept C2776694085 @default.
- W2033021519 hasConcept C2777546739 @default.
- W2033021519 hasConcept C2778336483 @default.
- W2033021519 hasConcept C2780427987 @default.
- W2033021519 hasConcept C2780456651 @default.
- W2033021519 hasConcept C2781413609 @default.
- W2033021519 hasConcept C2908647359 @default.
- W2033021519 hasConcept C3019054536 @default.
- W2033021519 hasConcept C71924100 @default.
- W2033021519 hasConcept C90924648 @default.
- W2033021519 hasConcept C99454951 @default.
- W2033021519 hasConceptScore W2033021519C121608353 @default.
- W2033021519 hasConceptScore W2033021519C126322002 @default.
- W2033021519 hasConceptScore W2033021519C141071460 @default.
- W2033021519 hasConceptScore W2033021519C143998085 @default.
- W2033021519 hasConceptScore W2033021519C167135981 @default.
- W2033021519 hasConceptScore W2033021519C2776694085 @default.
- W2033021519 hasConceptScore W2033021519C2777546739 @default.
- W2033021519 hasConceptScore W2033021519C2778336483 @default.
- W2033021519 hasConceptScore W2033021519C2780427987 @default.
- W2033021519 hasConceptScore W2033021519C2780456651 @default.
- W2033021519 hasConceptScore W2033021519C2781413609 @default.
- W2033021519 hasConceptScore W2033021519C2908647359 @default.
- W2033021519 hasConceptScore W2033021519C3019054536 @default.
- W2033021519 hasConceptScore W2033021519C71924100 @default.
- W2033021519 hasConceptScore W2033021519C90924648 @default.
- W2033021519 hasConceptScore W2033021519C99454951 @default.
- W2033021519 hasIssue "5" @default.
- W2033021519 hasLocation W20330215191 @default.
- W2033021519 hasLocation W20330215192 @default.
- W2033021519 hasOpenAccess W2033021519 @default.
- W2033021519 hasPrimaryLocation W20330215191 @default.
- W2033021519 hasRelatedWork W2046076775 @default.
- W2033021519 hasRelatedWork W2086820043 @default.
- W2033021519 hasRelatedWork W2091720821 @default.
- W2033021519 hasRelatedWork W2113780324 @default.
- W2033021519 hasRelatedWork W2143178874 @default.
- W2033021519 hasRelatedWork W2369685086 @default.
- W2033021519 hasRelatedWork W2388730008 @default.
- W2033021519 hasRelatedWork W2418999078 @default.
- W2033021519 hasRelatedWork W3215662100 @default.
- W2033021519 hasRelatedWork W4253125675 @default.
- W2033021519 hasVolume "36" @default.
- W2033021519 isParatext "false" @default.
- W2033021519 isRetracted "false" @default.
- W2033021519 magId "2033021519" @default.
- W2033021519 workType "article" @default.